Search company, investor...
Search
Ultivue company logo

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

ultivue.com

Founded Year

2015

Stage

Series D | Alive

Total Raised

$97.15M

Last Raised

$50M | 1 yr ago

Mosaic Score

+20 points in the past 30 days

What is a Mosaic Score?
The Mosaic Score is an algorithm that measures the overall financial health and market potential of private companies.

About Ultivue

Ultivue develops reagent-driven solutions for high-definition biological imaging in situ, combining unlimited multiplexing at high speed with high spatial resolution. Ultivue's proprietary reagents, instruments, and bioinformatics tools will enable researchers and clinicians to realize the promise of personalized medicine through better matching of patients to therapeutic options.

Ultivue Headquarters Location

763D Concord Ave.

Cambridge, Massachusetts, 02138,

United States

617-945-2662

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Ultivue

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Ultivue is included in 1 Expert Collection, including Biopharma Tech.

B

Biopharma Tech

5,241 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Ultivue Patents

Ultivue has filed 18 patents.

The 3 most popular patent topics include:

  • Molecular biology
  • Biotechnology
  • Microscopy
patents chart

Application Date

Grant Date

Title

Related Topics

Status

9/13/2018

7/12/2022

Molecular biology, Monoclonal antibodies, Proteins, Biotechnology, Immune system

Grant

Application Date

9/13/2018

Grant Date

7/12/2022

Title

Related Topics

Molecular biology, Monoclonal antibodies, Proteins, Biotechnology, Immune system

Status

Grant

Latest Ultivue News

08:00 EDT ARCH Venture Partners Announces Promotions and New Appointment

Jun 7, 2022

News provided by Share this article Share this article CHICAGO, June 7, 2022 /PRNewswire/ -- ARCH Venture Partners today announced several key promotions and the appointment of Olivia Zetter as Strategic Advisor and Venture Partner. Key promotions include: Sean Kendall to Partner, Europe Corey Ritter to Principal Nilay Thakar, Ph.D., to Principal "We're delighted to have Ari, Sean, Corey and Nilay expand their roles on our investment team working with both life sciences and physical sciences companies," said ARCH Co-founder and Managing Director Keith Crandell. "Each of them started with ARCH at the Associate or Analyst level and have earned their way onto this team through solid and insightful work and by applying their broad skill sets. They have all been engaged in creating new companies and supporting the development of established portfolio firms. We're fortunate to have talent of this caliber in our firm and it is a privilege to work with them." Dr. Ari Nowacek, Partner, joined as an Analyst in 2015. Dr. Nowacek is a co-founder of HiberCell, Walden Biosciences, and ROME Therapeutics, and was instrumental in the development of Ultivue and Arbor Biotechnologies. Dr. Nowacek is a physician-scientist by training with over 25 peer-reviewed publications and greater than 400 citations in the areas of oncology, neuroscience, virology, and antiretroviral therapeutic development. His research has led to seven issued patents for therapeutic and R&D applications. Dr. Nowacek holds a B.S. in Biology and a B.S. in Psychology from the University of Indiana-Bloomington where he graduated Magna Cum Laude and was elected to Phi Beta Kappa. He also holds an M.D. and Ph.D. from the University of Nebraska Medical Center and an M.B.A. from the University of Nebraska-Omaha. He subsequently completed a medical residency in pathology and post-doctoral research at The University of Chicago and Massachusetts General Hospital. He serves as a board member for HiberCell and Walden Biosciences, and as a board observer for Arbor Biotechnologies, ROME Therapeutics, and Ultivue. Sean Kendall, Partner (Europe), joined as an Analyst in 2015. He is a co-founder of Vizgen and Scale Biosciences, contributed to the formation of and funding of AIRNA, and led ARCH's investment in Lightcast Discovery. Kendall drove business development efforts for other ARCH portfolio companies, including Twist Bioscience, Encodia, Singleron Biotechnologies, Oxford Nanoimaging, and Ultivue. Kendall holds a B.S. and M.S. in Chemical Engineering from Stanford University, and an M.B.A. on the Dean's Honor List from The University of Chicago. He serves as a board member at AIRNA and Encodia, and as a board observer for Vizgen and others. Corey Ritter, Principal, joined as an Associate in 2018. Ritter is a co-founder of Vizgen, Scale Biosciences, and others in development, and led investments in Slingshot Biosciences, Quantum Circuits, and Singleron Biotechnologies. He also supports business development efforts at DA32 Life Science Tech Acquisition Corp. Ritter holds a B.A. in Astrophysics from Princeton University and completed his M.B.A. at The University of Chicago. He is a board member at Slingshot Biosciences and a board observer at Vizgen, Scale Biosciences, and Quantum Circuits. Dr. Nilay Thakar, Principal, joined as an Associate in 2018. Dr. Thakar is a co-founder of Skylark Bio and serves as its Head of Business Development, and supported ARCH's investment efforts in Ally Therapeutics and One BioMed. He has authored eight peer-reviewed publications with greater than 250 citations in the areas of neuroscience, stem cell biology, intracellular signaling, and epigenetics. Dr. Thakar holds a B.S. in Biochemistry with high-distinction honors and a Ph.D. in Cell Biology from the University of Queensland in Australia. He also completed his M.B.A. at The University of Chicago Booth School of Business. He serves as a board member of AgBiome and as a board observer at Skylark Bio, Arbor Biotechnologies, and One BioMed. ARCH also announced that security expert Olivia Zetter was appointed Strategic Advisor and Venture Partner. Zetter brings broad experience in national security and emerging technology issues that bridge public and private sectors. She most recently served as Head of Government Affairs and AI Strategy at National Resilience, a first-of-its-kind manufacturing and technology company dedicated to broadening access to complex medicines and protecting biopharmaceutical supply chains against disruption. She previously held multiple positions in government, including Director for Research and Analysis at the National Security Commission on Artificial Intelligence, Foreign Affairs Officer at the Department of State's Office of the Coordinator for Cyber Issues, and Special Assistant to the Chairman of the Joint Chiefs of Staff at the United States Department of Defense. Zetter holds a B.A. in International Relations from American University, Magna Cum Laude, Phi Beta Kappa, and a Master of Public Policy from Harvard University's Kennedy School of Government. "Olivia brings to ARCH a deep understanding of artificial intelligence and cyber security, both issues of critical importance to the development of the national and global biotechnology industries. Her experience and counsel will greatly enhance the ability of our portfolio companies to expand and operate optimally around the world," said ARCH Co-founder and Managing Director Robert Nelsen. About ARCH Venture Partners ARCH Venture Partners invests in advanced technology companies and is one of the largest early-stage technology venture firms in the United States. The firm is a recognized leader in commercializing technologies developed at academic institutions, corporate research groups and national laboratories. ARCH invests primarily in companies it co-founds with leading scientists and entrepreneurs, bringing innovations in life sciences and physical sciences to market. For more information, visit www.archventure.com . Contact:

Ultivue Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Ultivue Rank

  • When was Ultivue founded?

    Ultivue was founded in 2015.

  • Where is Ultivue's headquarters?

    Ultivue's headquarters is located at 763D Concord Ave., Cambridge.

  • What is Ultivue's latest funding round?

    Ultivue's latest funding round is Series D.

  • How much did Ultivue raise?

    Ultivue raised a total of $97.15M.

  • Who are the investors of Ultivue?

    Investors of Ultivue include ARCH Venture Partners, Applied Ventures, Northpond Ventures, Ally Bridge Group, Tao Capital Partners and 8 more.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.